Butyrate specifically exhibits potent anti-inflammatory effects in intestinal macrophages by inhibiting nitric oxide, IL-6, and IL-12 production through HDAC-dependent pathways, suggesting therapeutic potential for inflammatory bowel disease (IBD) [37]. Here, HDAC9 is linked to inflammatory bowel disease.